SecurityAMD / Advanced Micro Devices, Inc. (007903107)
IndustrySemiconductors and Related Devices
Common Shares Outstanding969,110,191 shares (as of 2017-12-30)
Total Insiders31
Total Directors20
Total Officers10

Stock Insider Trading (from SEC Form 4)

Advanced Micro Devices, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

AMD / Advanced Micro Devices, Inc. insiders include AL MUHAIRI AL MOKARRAB WALEED, BYRNE JOHN, WOLIN HARRY A, DONOFRIO NICHOLAS M, CONWAY CRAIG A, YAHIA AHMED, ANDERSON JAMES ROBERT, MARREN JOHN W, MUBADALA DEVELOPMENT CO PJSC, Denzel Nora, DURCAN DERMOT MARK, and BARNES W MICHAEL, HARDING JOHN R, GHILARDI EMILIO, KUMAR DEVINDER, EDELMAN MARTIN L, HOUSEHOLDER JOSEPH A, SMITH DARLA M, Norrod Forrest Eugene, TALWALKAR ABHIJIT Y, INGLIS MICHAEL J, CHOW HENRY, Claflin Bruce L., Su Lisa T, PALMER ROBERT B, READ RORY P, EBERHART PAULETT, Mubadala Investment Co PJSC CALDWELL JOHN EDWARD, Papermaster Mark D, SEIFERT THOMAS J, .

Insider Roster

Insider Dir Off 10% Shares Owned
ANDERSON JAMES ROBERT SVP & GM, CG
X 223,773
Papermaster Mark D Chief Technology Officer & SVP
X 1,057,949
KUMAR DEVINDER SVP, CFO & Treasurer
X 408,333
TALWALKAR ABHIJIT Y Director
X
CALDWELL JOHN EDWARD Director
X
MARREN JOHN W Director
X
Denzel Nora Director
X
YAHIA AHMED Director
X
INGLIS MICHAEL J Director
X
DURCAN DERMOT MARK Director
X
HOUSEHOLDER JOSEPH A Director
X
Norrod Forrest Eugene SVP & GM DESG
X 631,272
DONOFRIO NICHOLAS M Director
X 363,721
Su Lisa T President & CEO, Director
X X 2,050,317
WOLIN HARRY A SVP, GC & Corporate Secretary
X 1,100,458
SMITH DARLA M
11,077
Mubadala Investment Co PJSC Director, 10% Owner
X X 131,906,166
Claflin Bruce L. Director
X 638,902
MUBADALA DEVELOPMENT CO PJSC Director, 10% Owner
X X
CHOW HENRY Director
X
HARDING JOHN R Director
X
EDELMAN MARTIN L Director
X
BARNES W MICHAEL Director
X
BYRNE JOHN SVP, GM CGBG
X
READ RORY P President and CEO, Director
X X
EBERHART PAULETT Director
X
CONWAY CRAIG A
PALMER ROBERT B
AL MUHAIRI AL MOKARRAB WALEED Director
X
SEIFERT THOMAS J SVP, CFO
X
GHILARDI EMILIO SVP, Chief Sales Officer
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-05-16 4 ANDERSON JAMES ROBERT S D 12.83 -125,000 223,773 2,871,008
2018-05-16 4 ANDERSON JAMES ROBERT M D 2.58 75,000 348,773
2018-05-15 4 Papermaster Mark D S D 12.29 -146,993 1,057,949 13,002,193
2018-05-15 4 Papermaster Mark D M D 5.76 146,993 1,204,942
2018-05-07 4 KUMAR DEVINDER S D 11.41 -113,519 408,333 4,659,080
2018-05-07 4 KUMAR DEVINDER M D 2.68 113,519 521,852
2018-04-30 4 Norrod Forrest Eugene S D 11.02 -25,000 631,272 6,956,617
2018-04-30 4 Norrod Forrest Eugene S D 11.02 -37,500 656,272 7,232,117
2018-04-30 4 Norrod Forrest Eugene M D 1.84 37,500 693,772
2018-04-26 4 DONOFRIO NICHOLAS M M D 13,653 363,721
2018-04-26 4 Denzel Nora M D 13,653 166,552
2018-04-26 4 YAHIA AHMED F D 11.04 -3,368 133,806
2018-04-26 4 YAHIA AHMED M D 13,653 137,174
2018-03-15 4 Papermaster Mark D S D 11.38 -150,000 1,057,949 12,039,460
2018-03-15 4 Papermaster Mark D M D 5.76 150,000 1,207,949
2018-03-07 4 Su Lisa T S D 12 -100,000 2,050,317 24,603,804
2018-02-28 4 KUMAR DEVINDER S D 12.45 -140,473 408,333 5,083,746
2018-02-21 4 ANDERSON JAMES ROBERT S D 11.93 -50,000 273,773 3,266,112
2018-02-21 4 ANDERSON JAMES ROBERT S D 11.92 -75,000 323,773 3,859,374
2018-02-21 4 ANDERSON JAMES ROBERT M D 2.58 75,000 398,773
2018-02-15 4 WOLIN HARRY A S D 12.27 -46,875 1,100,458 13,502,620
2018-02-15 4 WOLIN HARRY A M D 8.60 46,875 1,147,333
2018-02-14 4 Su Lisa T S D 12.05 -25,000 2,150,317 25,911,320
2018-02-14 4 Su Lisa T S D 12 -89,452 2,175,317 26,103,804
2018-02-14 4 Su Lisa T S D 12.05 -66,972 2,264,769 27,290,466
2018-02-14 4 Su Lisa T M D 5.87 26,952 2,331,741
2018-02-14 4 Su Lisa T M D 5.66 129,472 2,304,789
2018-02-12 4 Norrod Forrest Eugene S D 11.57 -25,000 656,272 7,593,067
2018-02-12 4 Norrod Forrest Eugene S D 11.58 -37,500 681,272 7,889,130
2018-02-12 4 Norrod Forrest Eugene M D 1.84 37,500 718,772
2018-02-06 4 Papermaster Mark D S D 11.57 -100,000 1,057,949 12,240,470
2018-02-05 4 DONOFRIO NICHOLAS M J D 11.56 127,282 350,068
2018-01-31 4 KUMAR DEVINDER S D 13.43 -32,387 548,806 7,370,465
2018-01-31 4 KUMAR DEVINDER S D 13.43 -35,589 581,193 7,805,422
2018-01-31 4 KUMAR DEVINDER M D 5.87 35,589 616,782
2018-01-16 4 Papermaster Mark D S D 12.08 -173,630 1,157,949 13,988,024
2018-01-15 4 Papermaster Mark D M D 386,390 1,331,579
2018-01-16 4 WOLIN HARRY A S D 12.08 -75,046 1,100,458 13,293,533
2018-01-15 4 WOLIN HARRY A M D 218,954 1,175,504
2018-01-16 4 KUMAR DEVINDER S D 12.08 -117,120 581,193 7,020,811
2018-01-15 4 KUMAR DEVINDER M D 257,593 698,313
2018-01-03 4 Norrod Forrest Eugene S D 11.61 -25,000 681,272 7,909,568
2018-01-03 4 Norrod Forrest Eugene S D 11.61 -37,500 706,272 8,199,818
2018-01-03 4 Norrod Forrest Eugene M D 1.84 37,500 743,772
2017-12-28 4 Papermaster Mark D S D 10.51 -20,000 945,189 9,933,936
2017-12-27 4 Papermaster Mark D S D 10.62 -34,330 965,189 10,250,307
2017-12-26 4 Papermaster Mark D M D 68,680 999,519
2017-12-27 4 Norrod Forrest Eugene S D 10.62 -29,178 706,272 7,500,609
2017-12-26 4 Norrod Forrest Eugene M D 68,680 735,450
2017-12-27 4 WOLIN HARRY A S D 10.62 -18,967 956,550 10,158,561
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)
AMD: Advanced Micro Devices Stock Analysis and Research Report

2017-09-28 - Asif

We are a global semiconductor company with facilities around the world. Within the global semiconductor industry, we offer primarily: x86 microprocessors, as standalone devices or as incorporated as an accelerated processing unit (APU), chipsets, discrete graphics processing units (GPUs) and professional graphics processors; and server and embedded processors, semi-custom System-on-Chip (SoC) products and technology for game consoles. We also license portions of our intellectual property portfolio. In this section, we will describe the general financial condition and the results of operations of Advanced Micro Devices, Inc. and its wholly-owned subsidiaries (collectively, “us,” “our” or “AMD”), including a discussion of our results of operations for the quarter and six months ended July 1, 2017 compared to the quarter and six months ended June 25, 2016 , an analysis of changes in our financial condition and a discussion of our contractual obligations. We believe our fin...

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

Business News Roundup, May 23

3h sfgate
Intel, the biggest maker of computer processors, said it found another vulnerability related to the chip security flaws announced this year. (671-0)

Intel And Mobileye Are Tearing Down Nvidia's Self-Driving Car Strategy

10h seekingalpha
Intel’s $15.3 billion gamble in purchasing Mobileye now looks judicious. Mobileye recently signed a contract to supply its self-driving technology/hardware to 8 million cars. (748-0)

Microsoft, Google find fresh flaw in chips, but risk is low

2018-05-21 reuters
(Reuters) - Cyber security researchers have found a new security flaw that affects a broad swath of modern computing chips and is related to the Spectre and Meltdown chip flaws that emerged in January. (722-0)

Germany calls on chip and hardware makers to tackle processor flaws

2018-05-18 reuters
BERLIN (Reuters) - Germany’s federal cyber agency called on chip and hardware-makers to address new vulnerabilities discovered in computer central processing units, but said no complete fix was possible at the moment. (672-1)

China’s Crypto-Chips King Sets His Sights on AI - Bloomberg

2018-05-17 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (874-1)